Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Significance: Glioblastoma is the most common and aggressive form of brain cancer. GBM patients typically respond poorly to conventional therapies. The tumor-suppressor protein 53 pathway is disrupted in a majority of GBM cases. Using a mouse model that mimics the progression of human GBM, we evaluate and optimize the therapeutic efficacy of functional p53 restoration in gliomas. We show that the efficacy of p53 restoration therapy in the animal model as well as in human GBM cells is improved markedly by an episodic dosing regimen that circumvents the selective pressure for adaptive resistance when p53 function is chronically restored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 2×
“For p53 sequencing analysis, cDNA was amplified with primers p53 forward: 5′-CCA TGG AGGAGT CAC AGT CG-3′ and p53 reverse: 5′-GCA GAG GCA GTC AGT CTG AGT C-3′ as described (37).”
BackgroundMethodSelf-citationInactivation of the p53 pathway in retinoblastoma
Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569 · cited 2×
“To model the therapeutic impact of p53 restoration in human gliomas of each class, we exposed human GBM cell lines (44) to 2, 2- bis(hydroxymethyl)- 3- quinuclidinone (Prima-1), a smallmolecular-weight compound that restores the defective conformation of mutant p53, rescuing competence for both DNA binding and activat…”
BackgroundMethodtwist is a potential oncogene that inhibits apoptosis
Maestro, R., Tos, A. P. D., Hamamori, Y., Krasnokutsky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, D. H., & Hannon, G. J. (1999) · Genes & Development · doi:10.1101/gad.13.17.2207 · Cited by 516
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490 · cited 1×
“Because p19 is the mediator of oncogenic Ras signaling (39, 42), we assayed p19 expression in both previously untreated tumors (p53ER OFF) and in tumors subjected to sustained restoration of p53 for 10 wk (p53ER-Restored Sustained) (Fig.”
MethodEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465 · cited 1×
“19), isocitrate dehydrogenase (IDH1/2) mutation (20), EGF receptor (EGFR) amplification (21), and p53 status (22) are all being assessed currently as potential determinants of personalized GBM therapy.”
BackgroundMdm2 is critically and continuously required to suppress lethal p53 activity in vivo
Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256
Self-citation
Cited by
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Mitochondria-mediated apoptosis in mammals
Xiong, S., Mu, T., Wang, G., & Jiang, X. (2014) · Protein & Cell · doi:10.1007/s13238-014-0089-1 · Cited by 398
Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.011 · Cited by 238
Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163
Patyka, M., Sharifi, Z., Petrecca, K., Mansure, J., Jean-Claude, B., & Sabri, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11197 · Cited by 42
“In a previous study using in vitro and in vivo models of primary and secondary GBM, functional p53-activating signals such as CDKN2A (p14ARF) were shown to be required for restoring p53 tumor-suppressor activities following treatment with PRIMA-1 [76].”
Background
Metadata
- Authors
- Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., & Evan, G. I.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-03-29
- Volume
- 110
- Issue
- 16
- Pages
- E1480-9
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2029617353
- Cited by
- 48
- References
- 12
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. https://app.cochat.ai/papers/10.1073/pnas.1219142110
- The paper
- Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., & Evan, G. I. (2013). Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1219142110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.